Breakthroughs in cancer gene therapy

Seminars in Oncology Nursing

Volumn 19, Issue 3, 2003, Pages 217-226

  Liu, Ke ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; LIPOSOME; PLASMID DNA; T LYMPHOCYTE RECEPTOR; TUMOR VACCINE;

ADENOVIRUS VECTOR; ADOPTIVE IMMUNOTHERAPY; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER THERAPY; CLINICAL PROTOCOL; FOWLPOX VIRUS; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HUMAN; MEDICAL LITERATURE; NONVIRAL GENE DELIVERY SYSTEM; NURSING; PATIENT EDUCATION; RETROVIRUS VECTOR; REVIEW; SUICIDE GENE THERAPY; TUMOR ESCAPE; TUMOR SUPPRESSOR GENE; VACCINIA VIRUS; ACTIVE IMMUNIZATION; CLINICAL TRIAL; GENETIC TRANSDUCTION; METHODOLOGY; NEOPLASM; NURSE ATTITUDE; ONCOLOGY NURSING;

CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; NURSE'S ROLE; ONCOLOGIC NURSING; TRANSDUCTION, GENETIC;

EID: 0142026121     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-2081(03)00049-4     Document Type: Article

References (74)

1. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346:1185-1193
2. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. N Engl J Med. 347:2002;1593-1603
3. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 9:1993;38-141
4. Schuler G.D., Boguski M.S., Stewart E.A., et al. A gene map of the human genome. Science. 274:1996;540-546
5. Venter J.C., Adams M.D., Myers E.W., et al. The sequence of the human genome. Science. 291:2001;1304-1351
6. Kootstra N.A., Verma I.M. Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol. 43:2002;413-439
7. Marconi P., Krisky D., Oligino T., et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A. 93:1996;11319-11320
8. Stavropoulos T.A., Strathdee C.A. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol. 72:1998;7137-7143
9. Wightman L., Kircheis R., Rossler V., et al. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J Gene Med. 3:2001;362-372
10. McKenzie D.L., Kwok K.Y., Rice K.G. A potent new class of reductively activated peptide gene delivery agents. J Biol Chem. 275:2000;9970-9977
11. Buchschacher G.L. Jr. Introduction to retroviruses and retroviral vectors. Somat Cell Mol Genet. 26:2001;1-11
12. Springett G.M., Moen R.C., Anderson S., et al. Infection efficiency of T lymphocytes with amphotroic retroviral vector is cell cycle dependent. J Virol. 63:1989;3865-3869
13. Morsy M.A., Gu M., Motzel S., et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A. 95:1998;7866-7871
14. Carroll M.W., Overwijk W.W., Chamberlain R.S., et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector A murine tumor model. Vaccine. 15:1997;387-394
15. Wang M., Bronte V., Chen P.W., et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol. 154:1995;4685-4692
16. Niidome T., Huang L. Gene therapy progress and prospects Nonviral vectors. Gene Ther. 9:2002;1647-1652
17. Farhood H., Gao X., Son K., et al. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann NY Acad Sci. 716:1994;23-34
18. Nishikawa M., Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull. 25:2002;275-283
19. McCormick F. Cancer gene therapy Fringe or cutting edge? Nat Rev Cancer. 1:2001;130-141
20. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature. 411:2001;380-384
21. Human gene therapy protocols. Office of Biotechnology Activities, National Institutes of Health. Available at: http://www4.od.nih.gov/oba/rac/ PROTOCOL.pdf.
22. Rosenberg S.A., Aebersold P., Cornetta K., et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 323:1990;570-578
23. Kawakami Y., Wang X., Shofuda T., et al. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol. 166:2001;2871-2877
24. Kawakami Y., Eliyahu S., Delgado C.H., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 91:1994;6458-6462
25. Kawakami Y., Eliyahu S., Delgado C.H., et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 91:1994;3515-3519
26. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 4:1998;321-327
27. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 3:2002;999-1005
28. Hodge J.W., Sabzevari H., Yafal A.G., et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59:1999;5800-5807
29. Nabel G.J., Gordon D., Bishop D.K., et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A. 93:1996;15388-15393
30. Greiner J.W., Zeytin H., Anver M.R., et al. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 62:2002;6944-6951
31. Rosenberg S.A. Cell transfer therapy clinical implications-Melanoma. Rosenberg S.A. Principles and Practice of Biologic Therapy of Cancer. 2000;323-333 Lippincott Williams & Wilkins, Philadelphia, PA
32. Kagi D., Ledermann B., Burki K., et al. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol. 14:1996;207-232
33. Hwu P., Yang J.C., Cowherd R., et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55:1995;3369-3373
34. Bolhuis R.L., Willemsen R.A., Lamers C.H., et al. Preparation for a phase I/II study using autologous gene modified T lymphocytes for treatment of metastatic renal cancer patients. Adv Exp Med Biol. 451:1998;547-555
35. Kessels H.W., Wolkers M.C., van den Boom M.D., et al. Immunotherapy through TCR gene transfer. Nat Immunol. 2:2001;957-961
36. Dudley M.E., Wunderlich J.R., Yang J.C., et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 25:2002;243-251
37. Rosenberg S.A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 233:1986;1318-1321
38. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 210:1989;474-484
39. Liu K., Rosenberg S.A. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol. 167:2001;6356-6365
40. Abonour R., Williams D.A., Einhorn L., et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med. 6:2000;652-658
41. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes paradigm for a prospective cancer control strategy. Cancer Res. 46:1986;5276-5281
42. Ram Z., Culver K.W., Oshiro E.M., et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 3:1997;1354-1361
43. Hall S.J., Canfield S.E., Yan Y., et al. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad. HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer. Gene Ther. 9:2002;511-517
44. Clayman G.L., Frank D.K., Bruso P.A., et al. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res. 5:1999;1715-1722
45. Swisher S.G., Roth J.A. Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin North Am. 11:2002;521-535
46. Buller R.E., Shahin M.S., Horowitz J.A., et al. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 9:2002;567-572
47. Mitry R.R., Sarraf C.E., Havlik R., et al. Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment. Hepatology. 31:2000;885-889
48. Spitz F.R., Nguyen D., Skibber J.M., et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 16:1996;3415-3422
49. Nemunaitis J., Swisher S.G., Timmons T., et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 18:2000;609-622
50. Ford A.C., Grandis J.R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck. 25:2003;67-73
51. Ueno N.T., Yu D., Hung M.C. E1A Tumor suppressor or oncogene?Preclinical and clinical investigations of E1A gene therapy. Breast Cancer. 8:2001;285-293
52. Bennett J.J., Delman K.A., Burt B.M., et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV102) for peritoneal cancer. Cancer Gene Ther. 9:2002;935-945
53. Nemunaitis J., Khuri F., Ganly I., et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 19:2001;289-298
54. Khuri F.R., Nemunaitis J., Ganly I., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 6:2000;879-885
55. Mabjeesh N.J., Zhong H., Simons J.W., et al. Gene therapy of prostate cancer current and future directions.A phase I trial of CV706, a replication-competent, prostate-specific antigen selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Endocr Relat Cancer. 9:2002;115-139
56. DeWeese T.L., van der Poel H., Li S., et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61:2001;7464-7472
57. Marshall E. Gene therapy. What to do when clear success comes with an unclear risk? Science. 298:2002;510-511
58. Kaiser J. Gene therapy. RAC's advice: Proceed with caution. Science. 298:2002;2113-2115
59. Marshall E. FDA halts all gene therapy trials at Penn. Science. 287:2000;565-567
60. Folkman J. Tumor angiogenesis Therapeutic implications. N Engl J Med. 285:1971;1182-1186
61. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin An endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285
62. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2:2002;727-739
63. Kershaw M.H., Westwood J.A., Zhu Z., et al. Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. Hum Gene Ther. 11:2000;2445-2452
64. Niederman T.M., Ghogawala Z., Carter B.S., et al. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A. 99:2002;7009-7014
65. Brooks P.C., Montgomery A.M., Rosenfeld M., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164
66. Vijayanathan V., Thomas T., Thomas T.J. DNA nanoparticles and development of DNA delivery vehicles for gene therapy. Biochemistry. 41:2002;14085-14094
67. Hood J.D., Bednarski M., Frausto R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2002;2404-2407
68. Payne Y., Brusso P. Gene therapy. Rieger P. Biotherapy: A Comprehensive Overview. 2nd ed:2001;421-457 Jones & Bartlett, Sudbury, MA
69. Calzone K.A., Tranin A. The scope of cancer genetics nursing practice. Tranin A.S., Masny A., Jenkins J. Genetics in Oncology Practice: Cancer Risk Assessment. 2003;13-22 Oncology Nursing Society, Pittsburgh, PA
70. Lea D.H. Gene therapy Current and future implications for oncology nursing practice. Semin Oncol Nurs. 13:1997;115-122
71. Oncology Nursing Society. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 2001;ONS, Pittsburgh, PA
72. Lea D.H. Gene therapy. Yarbro C.H., Frogge M.H., Goodman M., Groenwald S.L. Cancer Nursing: Principles and Practice. ed 5:2000;580-596 Jones and Bartlett, Boston, MA
73. Jenngst E. The NIH "points to consider" and the limits of human gene therapy. Hum Gene Ther. 1:1990;425-433
74. Human Genome Project Information-Gene Therapy. 2003;. Available at: http://www.ornl.gov. (accessed 3/20/03)